233 related articles for article (PubMed ID: 2068243)
1. A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population.
Edees S; Pullan CR; Hull D
Public Health; 1991 Mar; 105(2):91-7. PubMed ID: 2068243
[TBL] [Abstract][Full Text] [Related]
2. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
Usonis V; Bakasenas V; Kaufhold A; Chitour K; Clemens R
Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
[TBL] [Abstract][Full Text] [Related]
3. Effects and side effects of a new trivalent combined measles-mumps-rubella (MMR) vaccine.
Isozaki M; Kuno-Sakai H; Hoshi N; Takesue R; Takakura I; Kimura M; Hikino M; Mitsuda M
Tokai J Exp Clin Med; 1982 Sep; 7(5):547-50. PubMed ID: 7182947
[TBL] [Abstract][Full Text] [Related]
4. Serological evaluation of a measles, mumps, and rubella vaccine.
Robertson CM; Bennett VJ; Jefferson N; Mayon-White RT
Arch Dis Child; 1988 Jun; 63(6):612-6. PubMed ID: 3291787
[TBL] [Abstract][Full Text] [Related]
5. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
Crovari P; Gabutti G; Giammanco G; Dentico P; Moiraghi AR; Ponzio F; Soncini R
Vaccine; 2000 Jun; 18(25):2796-803. PubMed ID: 10812221
[TBL] [Abstract][Full Text] [Related]
6. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age.
Klinge J; Lugauer S; Korn K; Heininger U; Stehr K
Vaccine; 2000 Jul; 18(27):3134-40. PubMed ID: 10856793
[TBL] [Abstract][Full Text] [Related]
7. [The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella].
Samoĭlovich EO; Kapustik LA; Fel'dman EV; Ermolovich MA; Svirchevskaia EIu; Titov LP; Zakharenko DF; Belova EIu; Chernovetskiĭ MA; Korostik TS
Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):36-40. PubMed ID: 9783398
[TBL] [Abstract][Full Text] [Related]
8. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
[TBL] [Abstract][Full Text] [Related]
9. [Drug clinics. Drug of the month. A new measles-rubella-mumps vaccine (Priorix)].
Senterre J
Rev Med Liege; 1999 Feb; 54(2):122-4. PubMed ID: 10221066
[TBL] [Abstract][Full Text] [Related]
10. Combined vaccine against measles, mumps, rubella, and varicella.
Brunell PA; Novelli VM; Lipton SV; Pollock B
Pediatrics; 1988 Jun; 81(6):779-84. PubMed ID: 2835743
[TBL] [Abstract][Full Text] [Related]
11. Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response.
Halperin SA; McGrath P; Smith B; Houston T
J Pediatr; 2000 Jun; 136(6):789-94. PubMed ID: 10839878
[TBL] [Abstract][Full Text] [Related]
12. Re: V. Usonis et al.: Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children (Infection 26 [1998] 222-226).
Nalin D
Infection; 1999; 27(2):134-5. PubMed ID: 10219647
[No Abstract] [Full Text] [Related]
13. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children.
Vesikari T; Ohrling A; Baer M; Delem A; Bogaerts H; André FE
Acta Paediatr Scand; 1991 Nov; 80(11):1051-7. PubMed ID: 1661057
[TBL] [Abstract][Full Text] [Related]
14. Gender differences in the reactogenicity of measles-mumps-rubella vaccine.
Shohat T; Green MS; Nakar O; Ballin A; Duvdevani P; Cohen A; Shohat M
Isr Med Assoc J; 2000 Mar; 2(3):192-5. PubMed ID: 10774264
[TBL] [Abstract][Full Text] [Related]
15. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus.
Molyneaux PJ; Mok JY; Burns SM; Yap PL
J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316
[TBL] [Abstract][Full Text] [Related]
16. Pain and measles, mumps, and rubella vaccination.
Lyons R; Howell F
Arch Dis Child; 1991 Mar; 66(3):346-7. PubMed ID: 2025015
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells.
Just M; Berger R; Glück R; Wegmann A
Dev Biol Stand; 1986; 65():25-7. PubMed ID: 3549399
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
[TBL] [Abstract][Full Text] [Related]
19. [Immunization of healthy children with measles-mumps-rubella trivalent vaccine simultaneously given with varicella vaccine].
Takayama N; Kidokoro M; Suzuki K; Morita M
Kansenshogaku Zasshi; 1992 Jun; 66(6):776-80. PubMed ID: 1331262
[TBL] [Abstract][Full Text] [Related]
20. Duration of the immune response to MMR vaccine in children of two age-different groups.
Li Volti S; Giammanco-Bilancia G; Grassi M; Garozzo R; Gluck R; Giammanco G
Eur J Epidemiol; 1993 May; 9(3):311-4. PubMed ID: 8405317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
